4-氨基-2-羟基苯甲酰氯 | 36387-22-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-羟基苯甲酰氯
• 英文名称: 2-hydroxy-4-aminobenzoyl chloride
• 英文别名: 4-Amino-2-hydroxybenzoyl chloride
• CAS: 36387-22-1
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: SBSWVAPROLGDIT-UHFFFAOYSA-N

物化性质

• 沸点：
  354.4±32.0 °C(Predicted)
• 密度：
  1.472±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基-2-羟基苯甲酰氯 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 (E)-methyl 4-((2,5-dihydroxybenzylidene)amino)-2-hydroxybenzoate
  参考文献：
  名称：

  Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity

  摘要：

  The synthesis and structure-activity relationships of a series of [(hydroxybenzylidene)amino] salicylates and a series of [(hydroxybenzyl)amino] salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity are described. Their inhibitory potency was evaluated in vitro using ER 22 cell membranes (CCL 39 cells transfected with EGF receptor) as an enzyme source and the tridecapeptide RRSrc (RRLIEDAEYAARG) as substrate. Their cellular activity was measured by inhibition of the EGF-stimulated DNA synthesis of ER 22 cells. Chemical modifications were made to analyze the role of the different substituents. The amino series was found to be more active than the imino series. The hydroquinone moiety appears to be essential for tyrosine kinase inhibitory activity in the series of 5-[(2,5-dihydroxybenzyl)amino]salicylates. Comparison of the imino and amino series by molecular modeling techniques provides further evidence in support of the hypothesis that the important reduced linking chain, CH2NH, allows the correct positioning of the 2,5-dihydroxybenzyl ring, possibly in a cis-like conformational arrangement.

  DOI：

  10.1021/jm00077a014
• 作为产物：
  描述：

  4-氨基水杨酸 在 氯化亚砜 作用下， 反应 2.0h， 生成 4-氨基-2-羟基苯甲酰氯
  参考文献：
  名称：

  炎症性腸疾患の治療のための組成物及び方法

  摘要：

  This invention relates to compounds of Formula I and Formula II or their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers, and hydrates thereof. Pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II. Methods for treating or preventing inflammatory bowel diseases can be formulated for oral, oral cavity, rectal, topical, transdermal, transmucosal, intravenous, non-oral administration, syrup formulations, or injections. Such compositions can be used for the treatment of inflammatory bowel diseases, ulcerative colitis, mild to moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, cirrhosis, and idiopathic urticaria gastrointestinal diseases.【Selection figure】None

  公开号：

  JP2015522549A

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
  申请人：Cellix Bio Private Limited

  公开号：US20160120839A1

  公开（公告）日：2016-05-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

  该发明涉及公式I和公式II的化合物或其药用可接受盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。含有公式I或公式II化合物的有效量的药物组合物；以及治疗或预防炎症性肠病的方法可制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻度至中度克罗恩病、类风湿关节炎、炎症性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。
• Compositions and methods for the treatment of inflammatory bowel disease
  申请人：Kandula Mahesh

  公开号：US09498461B2

  公开（公告）日：2016-11-22

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

  该发明涉及式I和式II化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的式I或式II化合物的药物组合物；以及用于治疗或预防炎症性肠病的方法可以制成口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射剂。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻至中度的克罗恩病、类风湿关节炎、炎性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。
• 3,7-Disubstituted-3-cephem-4-carboxylic acids
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04350692A1

  公开（公告）日：1982-09-21

  Preparation of pharmaceutical composition comprising, treatment of human and animal diseases with, and compounds of, 3,7-disubstituted-3-cephem-4-carboxylic acid.

  含有3,7-二取代-3-头孢基-4-羧酸化合物的制药组合物的制备，以及用于治疗人类和动物疾病的方法。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Kandula Mahesh

  公开号：US20160122291A1

  公开（公告）日：2016-05-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other neuro-inflammatory diseases.

  该发明涉及公式I和公式II的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I或公式II化合物的有效量的药物组合物；以及治疗或预防多发性硬化症的方法可以制备为口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这些组合物可用于治疗神经退行性疾病和其他神经炎症性疾病。
• 多発性硬化症の治療のための組成物及び方法
  申请人：——

  公开号：JP2015518854A5

  公开（公告）日：2015-07-06